For the first time, scientists say, they have evidence that using a biologic drug to remove sticky beta amyloid plaques from ...

A long-term human trial has found that a discontinued drug halved the presentation of early-onset Alzheimer's disease in ...

Since becoming only the second Alzheimer's-modifying drug to gain American Federal Drug Administration approval in 2023, ...

Recent research suggests lecanemab may be less effective in females, raising important questions for future Alzheimer’s drug ...

Washington University-led research shows a small group of participants in an Alzheimer’s study experienced a significant ...

Research announced today is the first of its kind to suggest that anti-amyloid drugs can delay or even stop the progression of symptoms in people with early-onset Alzheimer's.

A recent trial on gantenerumab showed that the drug could reduce the risk of Alzheimer’s symptoms by 50% in pre-symptomatic ...

An early Alzheimer's treatment that removes amyloid plaques from the brain many years before symptoms arise may help delay ...

AN ALZHEIMER’S drug hailed as a ‘miracle’ medicine for dementia may cause life-threatening brain bleeds in a third of ...

Since becoming only the second Alzheimer's-modifying drug to gain American Federal Drug Administration approval in 2023, sales of lecanemab, known by its brand name Leqembi, have risen steadily, ...

A research team has found that lecanemab was probably less effective in females than males in its Phase 3 trial. However, there was insufficient evidence to say the drug was totally ineffective in ...